Antiviral agents for dengue virus

Yinghan Jiang; Yanran Wang; Yaqun Xu; Yuxin Tian; Mengyuan Zhao; Chenguang Shen; Yang Yang; Minghui Yang

doi:10.1016/j.virs.2025.11.009

Antiviral agents for dengue virus

Yinghan Jiang
, Yanran Wang
, Yaqun Xu
, Yuxin Tian
, Mengyuan Zhao
, Chenguang Shen^*
, Yang Yang
, Minghui Yang

^*Corresponding author for this work

Advanced Research Institute of Multidisciplinary Science

Research output: Contribution to journal › Review article › peer-review

Abstract

Dengue virus (DENV) is a mosquito-borne pathogen responsible for a spectrum of illnesses, including dengue fever, dengue hemorrhagic fever, and dengue shock syndrome. Nearly half of the global population is at risk of DENV infection, making it a pressing public health issue worldwide. The limited cross-protection among the four DENV serotypes (DENV1–4) and the phenomenon of antibody-dependent enhancement (ADE) have posed significant challenges to the development of effective dengue vaccines. Furthermore, there are currently no specific antiviral treatments available. This review provides an overview of DENV's key characteristics, clinical manifestations, and recent advancements in antiviral drug development— including the repurposing of approved drugs, peptide-based antiviral agents, therapeutic antibodies, natural products with antiviral potential, and host factor inhibitors— aiming to offer critical insights to inform strategies for managing and preventing dengue outbreaks.

Original language	English
Journal	Virologica Sinica
DOIs	https://doi.org/10.1016/j.virs.2025.11.009
Publication status	Accepted/In press - 2025

Keywords

Antiviral agents
Dengue virus
Flavivirus
Peptides drugs

Access to Document

10.1016/j.virs.2025.11.009

Cite this

@article{20e5e62013c94aab947f2eb675fb5027,

title = "Antiviral agents for dengue virus",

abstract = "Dengue virus (DENV) is a mosquito-borne pathogen responsible for a spectrum of illnesses, including dengue fever, dengue hemorrhagic fever, and dengue shock syndrome. Nearly half of the global population is at risk of DENV infection, making it a pressing public health issue worldwide. The limited cross-protection among the four DENV serotypes (DENV1–4) and the phenomenon of antibody-dependent enhancement (ADE) have posed significant challenges to the development of effective dengue vaccines. Furthermore, there are currently no specific antiviral treatments available. This review provides an overview of DENV's key characteristics, clinical manifestations, and recent advancements in antiviral drug development— including the repurposing of approved drugs, peptide-based antiviral agents, therapeutic antibodies, natural products with antiviral potential, and host factor inhibitors— aiming to offer critical insights to inform strategies for managing and preventing dengue outbreaks.",

keywords = "Antiviral agents, Dengue virus, Flavivirus, Peptides drugs",

author = "Yinghan Jiang and Yanran Wang and Yaqun Xu and Yuxin Tian and Mengyuan Zhao and Chenguang Shen and Yang Yang and Minghui Yang",

note = "Publisher Copyright: {\textcopyright} 2025",

year = "2025",

doi = "10.1016/j.virs.2025.11.009",

language = "English",

journal = "Virologica Sinica",

issn = "1674-0769",

publisher = "KeAi Communications Co.",

}

TY - JOUR

T1 - Antiviral agents for dengue virus

AU - Jiang, Yinghan

AU - Wang, Yanran

AU - Xu, Yaqun

AU - Tian, Yuxin

AU - Zhao, Mengyuan

AU - Shen, Chenguang

AU - Yang, Yang

AU - Yang, Minghui

PY - 2025

Y1 - 2025

N2 - Dengue virus (DENV) is a mosquito-borne pathogen responsible for a spectrum of illnesses, including dengue fever, dengue hemorrhagic fever, and dengue shock syndrome. Nearly half of the global population is at risk of DENV infection, making it a pressing public health issue worldwide. The limited cross-protection among the four DENV serotypes (DENV1–4) and the phenomenon of antibody-dependent enhancement (ADE) have posed significant challenges to the development of effective dengue vaccines. Furthermore, there are currently no specific antiviral treatments available. This review provides an overview of DENV's key characteristics, clinical manifestations, and recent advancements in antiviral drug development— including the repurposing of approved drugs, peptide-based antiviral agents, therapeutic antibodies, natural products with antiviral potential, and host factor inhibitors— aiming to offer critical insights to inform strategies for managing and preventing dengue outbreaks.

AB - Dengue virus (DENV) is a mosquito-borne pathogen responsible for a spectrum of illnesses, including dengue fever, dengue hemorrhagic fever, and dengue shock syndrome. Nearly half of the global population is at risk of DENV infection, making it a pressing public health issue worldwide. The limited cross-protection among the four DENV serotypes (DENV1–4) and the phenomenon of antibody-dependent enhancement (ADE) have posed significant challenges to the development of effective dengue vaccines. Furthermore, there are currently no specific antiviral treatments available. This review provides an overview of DENV's key characteristics, clinical manifestations, and recent advancements in antiviral drug development— including the repurposing of approved drugs, peptide-based antiviral agents, therapeutic antibodies, natural products with antiviral potential, and host factor inhibitors— aiming to offer critical insights to inform strategies for managing and preventing dengue outbreaks.

KW - Antiviral agents

KW - Dengue virus

KW - Flavivirus

KW - Peptides drugs

UR - https://www.scopus.com/pages/publications/105025114293

U2 - 10.1016/j.virs.2025.11.009

DO - 10.1016/j.virs.2025.11.009

M3 - Review article

C2 - 41314473

AN - SCOPUS:105025114293

SN - 1674-0769

JO - Virologica Sinica

JF - Virologica Sinica

ER -

Antiviral agents for dengue virus

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this